证券代码：000650 证券简称：仁和药业 公告编号：2024-036 仁和药业股份有限公司 关于全资子公司获得二冬汤颗粒药品注册证书的公告 本公司及其董事、监事、高级管理人员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上市许可持有人：江西药都樟树制药有限公司 受 理 号：CXZS2400003 证书编号：2024S02698 药品批准文号：国药准字 C20240006 审批结论：根据《中华人民共和国药品管理法》，经审查，本品符合药品注册的有 关规定，批准注册上市，发给药品注册证书。 二、药品的其他相关情况 二冬汤为国家中医药管理局发布的《古代经典名方目录（第一批）》第 80 首，出 自清•程国彭《医学心悟》卷三，由天冬、麦冬、天花粉、黄芩、知母、荷叶、人参和 甘草等组成，具有润肺清胃之功效。主治上消，症见烦渴不止、小便频数、脉数无力 等。 近日，仁和药业股份有限公司（以下简称"公司"）下属子公司江西药都樟树制 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发的关于二 冬汤颗粒的《药品注册证书》。现将相关情况公告如下： 一、药品的基本情况 药品名称：二冬汤颗粒 ...

证券代码：000650 证券简称：仁和药业 公告编号：2024-035 一、药品的基本情况 药品名称：铝碳酸镁咀嚼片 剂 型：片剂 规 格：0.5g 注册分类：化学药品 仁和药业股份有限公司 关于全资子公司收到药品补充申请批准通知书的公告 本公司及其董事、监事、高级管理人员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 近日，仁和药业股份有限公司（以下简称"公司"）下属子公司江西药都仁和制 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发的关于铝 碳酸镁咀嚼片的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评 价。现将相关情况公告如下： 受 理 号：CYHB2350887 通知书编号：2024B05114 截至本公告日，公司铝碳酸镁咀嚼片累计投入的研发费用约为人民币 500 万元（未 经审计）。 三、风险提示 上市许可持有人：江西药都仁和制药有限公司 原药品批准文号：国药准字 H20093696 药品注册标准编号：YBH27372024 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医疗器械 审评审批制度的意见》（国发（2015）4 ...

Financial Performance - The company's revenue for Q3 2024 was ¥786,304,880.57, representing a decrease of 30.83% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥78,501,931.30, down 57.30% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was ¥51,143,878.60, a decline of 67.00% compared to the previous year[2]. - Total operating revenue for the third quarter was CNY 3,150,637,679.36, a decrease of 17.5% compared to CNY 3,818,691,932.62 in the same period last year[13]. - The net profit for Q3 2024 was CNY 514,902,723.31, a decrease of 21.1% compared to CNY 652,593,697.28 in Q3 2023[14]. - The total profit for the period was CNY 683,366,510.37, down from CNY 858,734,254.05, a decrease of 20.4%[14]. - The basic earnings per share for Q3 2024 was CNY 0.2969, compared to CNY 0.3860 in Q3 2023, representing a decline of 23.1%[15]. - The company reported a total comprehensive income of CNY 514,902,723.31, down from CNY 652,593,697.28, reflecting a decrease of 21.1%[15]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,635,384,565.02, an increase of 2.56% from the end of the previous year[2]. - Total assets reached CNY 7,635,384,565.02, up from CNY 7,444,681,386.84 at the beginning of the period, indicating a growth of 2.6%[12]. - Non-current assets totaled CNY 2,989,033,782.13, an increase of 4.5% from CNY 2,860,970,209.82[12]. - Total liabilities decreased slightly to CNY 788,253,801.10 from CNY 790,180,602.21, a reduction of 0.2%[12]. - The company's equity attributable to shareholders increased to CNY 6,097,669,652.61 from CNY 5,993,036,906.06, reflecting a growth of 1.7%[12]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥298,363,941.70, an increase of 41.48% compared to the same period last year[2]. - The net cash flow from operating activities increased by 41.48% to ¥298,363,941.70 compared to the previous period, primarily due to higher government subsidies and lower operating expenses[6]. - The net cash flow from operating activities for Q3 2024 was approximately ¥298.36 million, an increase from ¥210.88 million in Q3 2023, representing a growth of 41.4%[17]. - The company's cash outflow from operating activities totaled approximately ¥3.25 billion, down from ¥3.77 billion in the same period last year, a decrease of 13.7%[17]. - The net cash flow from investment activities was negative at -¥2,172,121,641.49, a 41.13% increase in outflows compared to the previous period, mainly due to higher investments in financial products and long-term large deposits[6]. - The net cash flow from investment activities was negative at approximately -¥2.17 billion, worsening from -¥1.54 billion in Q3 2023[17]. - The total cash inflow from investment activities reached approximately ¥4.97 billion, up from ¥3.58 billion in the same period last year, indicating a growth of 38.9%[17]. Income and Expenses - Interest income decreased by 44.80% to ¥11,679,823.65, mainly due to a decline in certificate of deposit products and interest rates[6]. - Other income rose significantly by 110.51% to ¥112,551,014.14, attributed to increased government subsidies received compared to the same period last year[6]. - Investment income decreased by 60.08% to ¥21,523,313.36, primarily due to lower returns from financial products and recognized investment losses[6]. - The company's sales expenses were CNY 359,767,057.72, down from CNY 416,203,819.41, indicating a decrease of 13.6%[14]. - Research and development expenses decreased to CNY 23,201,544.61 from CNY 29,412,725.43, a reduction of 21.1% year-over-year[14]. - The financial expenses showed a significant improvement, with a net income of CNY -9,816,450.73 compared to CNY -18,093,820.98, indicating a reduction in financial costs[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 102,612[8]. - The largest shareholder, Renhe Group, holds 23.24% of the shares, amounting to 325,299,386 shares[8].

证券代码：000650 证券简称：仁和药业 公告编号：2024-033 仁和药业股份有限公司 4、规格：5mg、10mg 5、受理号：CYHB2300751 CYHB2300752 6、通知书编号：2024B04221 2024B04222 7、处方药/非处方药：处方药 8、药品批准文号：国药准字 H20247209 国药准字 H20247210 关于全资子公司获得药品补充申请批件的公告 本公司及其董事、监事、高级管理人员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 仁和药业股份有限公司全资子公司江西药都仁和制药有限公司近日收到国家药品 监督管理局核准签发的关于他达拉非片的《药品补充申请批准通知书》。现将相关情况 公告如下： 一、药品基本情况 1、药物名称：他达拉非片 2、剂型：片剂 3、注册分类：化学药品 3、公司首次提交本品生产申请的受理时间为 2023 年 04 月 11 日（受理号： CYHB2300751 CYHB2300752）。截至本公告日，公司他达拉非片（5mg、10mg）累计投 入的研发费用约为人民币 500 万元（未经审计）。 三、对公司的影响和风险提示 公司 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥2,364,332,798.79, a decrease of 11.84% compared to ¥2,681,918,127.26 in the same period last year[12]. - Net profit attributable to shareholders was ¥337,175,704.35, down 5.43% from ¥356,548,925.17 in the previous year[12]. - Basic earnings per share were ¥0.2409, a decrease of 5.42% from ¥0.2547 in the same period last year[12]. - The weighted average return on equity was 5.48%, down from 6.02% in the previous year[12]. - The company reported a net loss of CNY 953,370.00 for the period, with total assets amounting to CNY 2,372,940.00[44]. - The total revenue for the first half of 2024 is CNY 22,053,699.34, compared to CNY 56,093,643.33 in the same period last year, indicating a significant decline[43]. - The company reported a significant increase in investment income, amounting to ¥9,343,832.48, contributing 1.72% to the total profit[34]. - The company reported a total of 1,424,826.61 CNY for advertising, brand planning, and packaging design fees from Shenzhen Shining Marketing Planning Co., Ltd., accounting for 142.48 thousand CNY in related transactions[80]. Cash Flow and Liquidity - The net cash flow from operating activities was ¥360,721,054.30, an increase of 227.62% compared to ¥110,102,202.28 in the same period last year[12]. - The company's cash and cash equivalents decreased by 62.15% to ¥989,491,010.74, down from ¥2,614,528,883.12 at the beginning of the period[29]. - The cash inflow from financing activities was ¥71,610,000.00, compared to no inflow in the previous year, indicating a positive shift in financing[125]. - The company's cash outflow for paying dividends and interest was significantly reduced to ¥17,183,054.46 from ¥279,987,646.80, a decrease of about 93.8%[125]. - The total cash outflow from operating activities was ¥2,266,703,430.53, down from ¥2,626,144,301.80, indicating a reduction of about 13.7%[123]. Assets and Liabilities - Total assets at the end of the reporting period were ¥8,039,789,740.13, reflecting a growth of 7.99% from ¥7,444,681,386.84 at the end of the previous year[12]. - The company's total liabilities decreased by 44.57% in other current liabilities, primarily due to reduced contract liabilities[30]. - Total liabilities increased to CNY 1,008,745,632.73, up from CNY 790,180,602.21, representing a growth of approximately 27.7%[114]. - The company's total equity decreased to CNY 7,031,044,107.40 from CNY 6,654,500,784.63, a decline of approximately 5.6%[114]. Research and Development - The company is committed to enhancing its research and development capabilities, particularly in the field of traditional Chinese medicine[17]. - Research and development investment decreased by 27.41% to ¥19,447,518.48, down from ¥26,790,514.51 in the previous year[29]. - The company has increased its investment in research and development, enhancing its innovation capabilities and product technology content[27]. Market and Product Development - Approximately 80% of the company's pharmaceutical revenue comes from over-the-counter (OTC) products, with a focus on gynecology and pediatrics, while also expanding into ophthalmology and respiratory fields[17]. - The company aims to continue expanding its product line and market reach while maintaining a focus on health-related products[16]. - The company is actively developing new products, including various traditional Chinese medicine formulations aimed at treating conditions such as stroke and respiratory issues[18]. - The company has established a sales network across 30 provinces and regions in China, enhancing its product offerings and market presence[16]. Corporate Governance and Shareholder Relations - The annual shareholders' meeting had a participation rate of 37.83%, where multiple key proposals were approved, including the financial report and profit distribution plan[62]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[64]. - The employee stock ownership plan includes 101 employees holding a total of 15,500,000 shares, representing 1.11% of the company's total equity[65]. - The company has established a management committee for the second phase of its employee stock ownership plan, ensuring proper oversight and management[67]. Environmental Responsibility - The company has consistently met national environmental standards and has not faced any significant environmental issues or penalties[74]. - The company invested CNY 1,057,408.31 in environmental governance and paid CNY 15,937.44 in environmental protection tax[72]. - The company has implemented measures to reduce carbon emissions by optimizing production schedules and reducing boiler operation time[73]. Risk Management - There were no significant risks that materially affected the company's operations during the reporting period[3]. - The company faces risks from industry policy adjustments, particularly due to ongoing reforms in the medical system, which may significantly affect production and sales[59]. - The company has implemented a strict quality control system to mitigate risks associated with drug safety and product quality issues[60]. Related Party Transactions - No significant related party transactions occurred during the reporting period, including asset or equity acquisitions or sales[84]. - The total rental income recognized during the reporting period amounted to CNY 4,122,624.96[94]. - The company engaged in transactions with Jiangxi Renhe Tang Pharmaceutical Chain Co., Ltd. for purchasing goods amounting to 3,048.14 CNY, representing 0.3 thousand CNY in related transactions[80]. Financial Reporting and Compliance - The semi-annual financial report was not audited, indicating that the figures presented are preliminary[111]. - The company prepares financial statements in accordance with the Accounting Standards for Business Enterprises and relevant regulations, ensuring a true and complete reflection of its financial status and operating results[147]. - The company has evaluated its ability to continue as a going concern for the next 12 months and found no significant doubts regarding its ongoing viability[145].

2024 上半年非经营性资金占用及其他关联资金往来情况汇总表 编制单位：仁和药业股份有限公司 单位：万元 | 非经营性 | | 占用方与上市公司 | 上市公司核 | 2024 年期 | 2024 上半年往来 | 2024 上半 年往来资金 | 2024 上半年 | 2024 年 6 月 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 资金占用 | 资金占用方名称 | 的关联关系 | 算的会计科 | 初往来资金 | 累计发生金额 | 的利息（如 | 偿还累计发生 | 末往来资金 | 原因 | 占用性质 | | | | | 目 | 余额 | （不含利息） | 有） | 金额 | 余额 | | | | 控股股东、实 | | | | | | | | | | 非经营性占用 | | 际控制人及其 附属企业 | | | | | | | | | | 非经营性占用 | | | | | | | | | | - | | | | 小计 | — | — | — | - | - | - | - | - | | — | | 前 ...

此议案表决结果：同意票 9 票，反对票 0 票，弃权票 0 票，通过。 二、审议通过了《关于公司 2024 年半年度募集资金存放与使用情况的专项 报告的议案》 报告期内，公司严格按照《深圳证券交易所股票上市规则》《深圳证券交易 所上市公司自律监管指引第 1 号--主板上市公司规范运作》等相关规定，及时、 真实、准确、完整地披露募集资金的使用及存放情况，公司募集资金的实际使用 合法、合规，未发现违反法律、法规及损害股东利益的行为，不存在违规使用募 集资金的情形。 公司编制的《关于 2024 年半年度募集资金存放与使用情况的专项报告》真 实、客观地反映了 2024 年 1-6 月份公司募集资金的存放和实际使用情况。 证券代码：000650 证券简称：仁和药业 公告编号：2024-029 仁和药业股份有限公司 第九届董事会第二十一次会议决议公告 本公司及其董事、监事、高级管理人员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 仁和药业股份有限公司第九届董事会第二十一次会议通知于 2024 年 8 月 16 日以直接送达、电子邮件等方式发出，会议于 2024 年 8 月 26 日以现场与通 ...

仁和药业股份有限公司 2024 年上半年募集资金存放与使用情况的专项报告 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集资金管 理和使用的监管要求（2022 年修订）》、深圳证券交易所发布的《深圳证券交易所上市 公司自律监管指引第 1 号——主板上市公司规范运作》等有关规定，仁和药业股份有限 公司（以下简称"公司"或"本公司"）董事会编制了截至 2024 年 6 月 30 日止募集资 金年度存放与实际使用情况的专项报告。 一、 募集资金基本情况 经中国证券监督管理委员会《关于核准仁和药业股份有限公司非公开发行股票的批复》 （证监许可[2020]2255 号）核准，本公司可向发行对象非公开发行普通股（A 股）不超过 371,502,022 股。根据发行结果，公司本次实际向发行对象发行普通股（A 股）161,598,158 股，每股面值人民币 1.00 元，每股发行认购价格为人民币 5.16 元，本公司共募集资金总额 人民币 833,846,495.28 元，扣除与发行有关的费用总额人民币 10,957,389.86 元（不含增 值税），实际募集资金净额为人民币 822,889,105.4 ...

证券代码：000650 证券简称：仁和药业 公告编号：2024-030 仁和药业股份有限公司 第九届监事会第十五次会议决议公告 本公司及其董事、监事、高级管理人员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 仁和药业股份有限公司第九届监事会第十五次会议通知于 2024 年 8 月 16 日 以直接送达、电子邮件等方式发出，会议于 2024 年 8 月 26 日以现场与通讯结合 方式在南昌元创国际 18 层公司会议室召开。会议应到监事 5 人，实到监事 5 人， 监事会主席罗晚秋女士主持本次会议，会议符合《公司法》和《公司章程》的有 关规定。经与会监事认真审议，会议审议通过了如下议案： 一、审议通过了《公司 2024 年半年度报告全文及摘要的议案》 1、经审核，监事会认为董事会编制和审议仁和药业股份有限公司 2024 年半 年度报告的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、 完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大 遗漏。 2、2024 年半年度报告的内容和格式符合中国证监会和证券交易所的各项规 定，所包含的信息能从各个方面真实地 ...

（二）社会上存在的已经或者将给公司造成不良影响的传言或信息； 仁和药业股份有限公司 舆情管理办法 (2024 年 08 月 26 日修订) 第一章 总则 第一条 为提高仁和药业股份有限公司（以下简称公司）应对各类舆情的能力，建立快速反 应和应急处置机制，及时、妥善处理各类舆情对公司股价、公司商业信誉及正常生产经营活 动造成的影响，切实保护投资者合法权益，根据《深圳证券交易所股票上市规则》等相关法 律法规的规定和《仁和药业股份有限公司章程》（以下简称《公司章程》），特制订本办法。 第二条 本办法所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较大影响的事件信 息。 第二章 舆情管理的组织体系及其工作职责 第三条 公司应对各类舆情（尤其是媒体质疑危机时）实行统一领导、统一组织、快速反应、 协同应对。 第四条 公司成立应对舆情管理工作领导小组（以下简称舆情工作组），由公司董事长任组 长，董事会秘书任副组长，成员由公司其他高级管理人员及各职能部门负责人组成。 第五 ...